129 related articles for article (PubMed ID: 38056161)
1. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
Feng R; Cheng D; Chen X; Yang L; Wu H
Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
[TBL] [Abstract][Full Text] [Related]
2. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
3. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
Xu X; Wang J
Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
5. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
7. Constructing and validating of m7G-related genes prognostic signature for hepatocellular carcinoma and immune infiltration: potential biomarkers for predicting the overall survival.
Liu P; Dong C; Shi H; Yan Z; Zhang J; Liu J
J Gastrointest Oncol; 2022 Dec; 13(6):3169-3182. PubMed ID: 36636051
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
Yu Y; Lou Y; Zhu J; Wang X
Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
10. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
Wang L; Wang Q; Li Y; Qi X; Fan X
J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
[TBL] [Abstract][Full Text] [Related]
11. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
[TBL] [Abstract][Full Text] [Related]
12. Analysis and Validation of Tyrosine Metabolism-related Prognostic Features for Liver Hepatocellular Carcinoma Therapy.
Cui Z; Liu C; Li H; Wang J; Li G
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38415454
[TBL] [Abstract][Full Text] [Related]
13. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
Front Genet; 2021; 12():785185. PubMed ID: 34917132
[No Abstract] [Full Text] [Related]
14. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of
Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
[TBL] [Abstract][Full Text] [Related]
16. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract][Full Text] [Related]
17. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
18. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
Yang Y; Zhao W; Du J; Wang Y
Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
[TBL] [Abstract][Full Text] [Related]
20. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis.
He Q; Fan B; Du P; Jin Y
Front Cell Dev Biol; 2022; 10():806989. PubMed ID: 35356272
[No Abstract] [Full Text] [Related]
[Next] [New Search]